Adi Mohanty
Algemeen Directeur bij BIORA THERAPEUTICS, INC.
Vermogen: 97 752 $ op 30-04-2024
Momenteel actieve connecties
| Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
|---|---|---|---|---|
| Brian Culley | M | 53 | 6 jaar | |
| Eric d'Esparbes | M | 56 | 5 jaar | |
| Jeffrey Alter | M | 61 | 5 jaar | |
| Robert W. Peabody | M | 69 |
Cell Cure Neurosciences Ltd.
 Cell Cure Neurosciences Ltd. BiotechnologyHealth Technology Cell Cure Neurosciences Ltd. develops cell therapies for neural degenerative diseases. Its therapeutic cells include retinal pigmented epithelial (RPE) cells and neural progenitor cells. The firm's cells are derived from human embryonic stem cells (hESCs), which are considered to be the gold standard source of cells for the development of stem cell therapies. The company was founded in 2005 and is headquartered in Jerusalem, Israel. | 9 jaar |
| David Schlachet | M | 78 |
Cell Cure Neurosciences Ltd.
Cell Cure Neurosciences Ltd. BiotechnologyHealth Technology Cell Cure Neurosciences Ltd. develops cell therapies for neural degenerative diseases. Its therapeutic cells include retinal pigmented epithelial (RPE) cells and neural progenitor cells. The firm's cells are derived from human embryonic stem cells (hESCs), which are considered to be the gold standard source of cells for the development of stem cell therapies. The company was founded in 2005 and is headquartered in Jerusalem, Israel. | 5 jaar |
| Andy Arno | M | 64 | 9 jaar | |
| Brian Kotzin | M | 74 | 5 jaar | |
| Jill Howe | F | 48 | 3 jaar | |
| Lynne Powell | F | 57 | 5 jaar | |
| Andrew Last | M | 64 | 9 jaar | |
| Jeffrey Allen Ferrell | M | 49 | 10 jaar | |
| Clarke Neumann | M | 60 | 10 jaar | |
| Michael Rhode | M | - | - | |
| Allison Luo | M | 50 | 7 jaar | |
| Robyn Hatton | F | - | 11 jaar | |
| Francine Del Ricci | F | - |
Cell Cure Neurosciences Ltd.
Cell Cure Neurosciences Ltd. BiotechnologyHealth Technology Cell Cure Neurosciences Ltd. develops cell therapies for neural degenerative diseases. Its therapeutic cells include retinal pigmented epithelial (RPE) cells and neural progenitor cells. The firm's cells are derived from human embryonic stem cells (hESCs), which are considered to be the gold standard source of cells for the development of stem cell therapies. The company was founded in 2005 and is headquartered in Jerusalem, Israel. | - |
| Michael D. West | M | - |
Cell Cure Neurosciences Ltd.
Cell Cure Neurosciences Ltd. BiotechnologyHealth Technology Cell Cure Neurosciences Ltd. develops cell therapies for neural degenerative diseases. Its therapeutic cells include retinal pigmented epithelial (RPE) cells and neural progenitor cells. The firm's cells are derived from human embryonic stem cells (hESCs), which are considered to be the gold standard source of cells for the development of stem cell therapies. The company was founded in 2005 and is headquartered in Jerusalem, Israel. | 22 jaar |
| Gary Hogge | M | 56 | 6 jaar | |
| Frank Lanza | M | 62 | 8 jaar | |
| Leslie Waltke | F | - | 12 jaar | |
| Paul W. Shabram | M | - | 2 jaar | |
| Raf Hofstein | M | 74 |
Cell Cure Neurosciences Ltd.
Cell Cure Neurosciences Ltd. BiotechnologyHealth Technology Cell Cure Neurosciences Ltd. develops cell therapies for neural degenerative diseases. Its therapeutic cells include retinal pigmented epithelial (RPE) cells and neural progenitor cells. The firm's cells are derived from human embryonic stem cells (hESCs), which are considered to be the gold standard source of cells for the development of stem cell therapies. The company was founded in 2005 and is headquartered in Jerusalem, Israel. | - |
| Benjamin Reubinoff | M | - |
Cell Cure Neurosciences Ltd.
Cell Cure Neurosciences Ltd. BiotechnologyHealth Technology Cell Cure Neurosciences Ltd. develops cell therapies for neural degenerative diseases. Its therapeutic cells include retinal pigmented epithelial (RPE) cells and neural progenitor cells. The firm's cells are derived from human embryonic stem cells (hESCs), which are considered to be the gold standard source of cells for the development of stem cell therapies. The company was founded in 2005 and is headquartered in Jerusalem, Israel. | 18 jaar |
| Rami Skaliter | M | 66 |
Cell Cure Neurosciences Ltd.
Cell Cure Neurosciences Ltd. BiotechnologyHealth Technology Cell Cure Neurosciences Ltd. develops cell therapies for neural degenerative diseases. Its therapeutic cells include retinal pigmented epithelial (RPE) cells and neural progenitor cells. The firm's cells are derived from human embryonic stem cells (hESCs), which are considered to be the gold standard source of cells for the development of stem cell therapies. The company was founded in 2005 and is headquartered in Jerusalem, Israel. | 7 jaar |
| Sharat Singh | M | - | - | |
| Ariella Kelman | M | - | 1 jaar |
Relatiegrafiek
Connectie in verschillende bedrijven
Oude connecties
| Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
|---|---|---|---|---|
| Cavan Redmond | M | 63 | 7 jaar | |
| Russell Skibsted | M | 65 | 4 jaar | |
| Ronald Andrews | M | 64 | 4 jaar | |
| Steve Cartt | M | 61 | 5 jaar | |
| Graham Hetherington | M | 65 | 6 jaar | |
| Don Bailey | M | 78 | 3 jaar | |
| Michael West | M | 71 | 16 jaar | |
| Stephana Patton | M | 54 | 2 jaar | |
| Pedro Lichtinger | M | 70 | 2 jaar | |
| Michael Mulroy | M | 58 | 2 jaar | |
| Ryan D. Chavez | M | 48 | 3 jaar | |
| William Annett | M | 70 | 4 jaar | |
| Susan Kilsby | F | 65 | 8 jaar | |
| James Bowling | M | 56 | 10 jaar | |
| Angus Russell | M | 68 | 14 jaar | |
| Ian Karp | M | - | 5 jaar | |
| William Haack | M | - | 2 jaar | |
| David R. Ginsburg | M | 71 | 8 jaar | |
| Tamara Joseph | F | 61 |
Transkaryotic Therapies, Inc.
 Transkaryotic Therapies, Inc. Miscellaneous Commercial ServicesCommercial Services Transkaryotic Therapies, Inc. (TKT) was a biopharmaceutical company with a major focus on developing products for the treatment of rare diseases. The company is used to markets one product, Replagal™, for the treatment of Fabry disease in the European Union and other countries, and was developing products for Hunter syndrome and Gaucher disease. The company was located in Cambridge, MA. | 1 jaar |
| William Burns | M | 76 | 8 jaar | |
| Melinda Griffith | F | 69 | - | |
| Surbhi Sarna | F | 38 | 2 jaar | |
| Flemming Ørnskov | M | 66 | 6 jaar | |
| Howard I. Scher | M | 72 | 3 jaar | |
| Dominic Blakemore | M | 54 | 4 jaar | |
| Albert Parker | M | 58 | 2 jaar | |
| Tony Kalajian | M | 54 | 4 jaar | |
| Doug Treco Treco | M | 66 |
Transkaryotic Therapies, Inc.
Transkaryotic Therapies, Inc. Miscellaneous Commercial ServicesCommercial Services Transkaryotic Therapies, Inc. (TKT) was a biopharmaceutical company with a major focus on developing products for the treatment of rare diseases. The company is used to markets one product, Replagal™, for the treatment of Fabry disease in the European Union and other countries, and was developing products for Hunter syndrome and Gaucher disease. The company was located in Cambridge, MA. | 17 jaar |
| Steven Gillis | M | 71 | 7 jaar | |
| David Stout | M | 70 | 6 jaar | |
| William Ciambrone | M | 60 |
Shire Human Genetic Therapies, Inc.
 Shire Human Genetic Therapies, Inc. Medical SpecialtiesHealth Technology Shire Human Genetic Therapies, Inc. develops medicines for the treatment of genetic diseases. The company was founded on July 7, 1988 and is headquartered in Lexington, MA. | 9 jaar |
| Padma Sundar | F | - | 3 jaar | |
| Mitchell Levine | M | - | - | |
| Ludovic Robin | M | - | 8 jaar | |
| Anne Minto | F | 70 | 8 jaar | |
| Damon Silvestry | M | 56 | 2 jaar | |
| Kristine C. Mechem | M | - | 4 jaar | |
| Jill Quigley | F | 49 | 4 jaar | |
| Debra Silberg | M | - | - | |
| Roger Adsett | M | 55 | 11 jaar | |
| Paul Streck | M | 60 | 2 jaar | |
| Iain Ward | M | - | 8 jaar | |
| Joanne Cordeiro | F | 66 | 8 jaar | |
| Perry Sternberg | M | 55 | 6 jaar | |
| Kim Dickinson | M | - | 2 jaar | |
| Daniel Dolan | M | 47 | 12 jaar | |
| Theresa Heggie | F | 63 | 3 jaar | |
| Joff Masukawa | M | - | - | |
| Simon Gibbins | M | 58 | 9 jaar | |
| Brooke Clarke | F | - | 5 jaar | |
| David MacKney | M | 56 | 3 jaar | |
| Konstantinos Andrikopoulos | M | 58 |
Transkaryotic Therapies, Inc.
Transkaryotic Therapies, Inc. Miscellaneous Commercial ServicesCommercial Services Transkaryotic Therapies, Inc. (TKT) was a biopharmaceutical company with a major focus on developing products for the treatment of rare diseases. The company is used to markets one product, Replagal™, for the treatment of Fabry disease in the European Union and other countries, and was developing products for Hunter syndrome and Gaucher disease. The company was located in Cambridge, MA. | 3 jaar |
| Jeffrey Leiden | M | 68 | 6 jaar | |
| David Mott | M | 58 | 2 jaar | |
| Kevin Rakin | M | 63 | 1 jaar | |
| Barry James Price | M | 80 | 14 jaar | |
| Patrick J. Langlois | M | 78 | 6 jaar | |
| Barbara H. Deptula | F | 69 | 8 jaar | |
| Kathleen Anne Nealon | F | 70 | 4 jaar | |
| Michael Rosenblatt | M | 76 | 1 jaar | |
| Mark Enyedy | M | 60 | 3 jaar | |
| Michael G. Vicari | M | - | 1 jaar | |
| Arthur Tzianabos | M | 60 | 8 jaar | |
| Anthony S. Murabito | M | - |
Transkaryotic Therapies, Inc.
Transkaryotic Therapies, Inc. Miscellaneous Commercial ServicesCommercial Services Transkaryotic Therapies, Inc. (TKT) was a biopharmaceutical company with a major focus on developing products for the treatment of rare diseases. The company is used to markets one product, Replagal™, for the treatment of Fabry disease in the European Union and other countries, and was developing products for Hunter syndrome and Gaucher disease. The company was located in Cambridge, MA. | 2 jaar |
| Deanna M. Petersen | F | 62 | 6 jaar | |
| John Mauldin | M | - | - | |
| David Colpman | M | 62 | 15 jaar | |
| Charlotte Sibley | F | 77 | 5 jaar | |
| Mario David Saltarelli | M | 63 | 2 jaar | |
| Ann Powell | F | 58 | 4 jaar | |
| Obed M. Cepeda | M | - |
Transkaryotic Therapies, Inc.
Transkaryotic Therapies, Inc. Miscellaneous Commercial ServicesCommercial Services Transkaryotic Therapies, Inc. (TKT) was a biopharmaceutical company with a major focus on developing products for the treatment of rare diseases. The company is used to markets one product, Replagal™, for the treatment of Fabry disease in the European Union and other countries, and was developing products for Hunter syndrome and Gaucher disease. The company was located in Cambridge, MA. | 1 jaar |
| Raymond Pratt | M | 73 | 7 jaar | |
| Georgia Erbez | F | 57 | 1 jaar | |
| Miguel Coego Rios | M | - | 8 jaar |
Statistieken
| Land | Connecties | % van het totaal |
|---|---|---|
| Verenigde Staten | 51 | 51.00% |
| Ierland | 45 | 45.00% |
| Israël | 7 | 7.00% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- Adi Mohanty
- Persoonlijk netwerk
